Initiate the first Phase 1/2 clinical study of VBI-2902
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 21 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- March 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“VBI expects to initiate the first Phase 1/2 clinical study of VBI-2902 in Canada in Q1 2021.”
What we found
Evidence strength A What the grades mean
The company initiated the Phase I/II clinical study of VBI-2902 in March 2021, which falls within the first quarter of 2021.
-
A VBI Vaccines Inc 10-Q filed 2021-05-10
“A Phase I/II study of the first of the two candidates (VBI-2902) initiated in March 2021” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 1/2 clinical study of VBI-2902
- Where
- Canada
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: supply chain issues
- Depends on
- Supplier
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you VBI Vaccines Inc? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C764195-022299 · Corrections policy